416
Participants
Start Date
August 20, 2024
Primary Completion Date
August 20, 2028
Study Completion Date
August 20, 2031
Nimotuzumab,Toripalimab,Cisplatin, albumin paclitaxel, capecitabine
Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2, Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14; Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
Nimotuzumab,Toripalimab,Cisplatin, Gemcitabine
Cisplatin 80 mg/m2, Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ,D1,D8; Triprolizumab injection 240mg, intravenous ; Nivolumab 400mg, intravenous; Q3W 1 cycle, 3 cycles
Sun Yat-sen University
OTHER